Faculty Summaries
Hossein Borghaei, DO
Hossein Borghaei, DO
Associate Professor
  • Director, Lung Cancer Risk Assessment

Recent Publications

  • Binyamin L, Alpaugh RK, Campbell KS, Borghaei H, Weiner LM. Rituximab-mediated ADCC is augmented by concomitant interference with inhibitory self-recognition by human NK cells. Blood. 2005;106:690A-691A.
  • Borghaei H, Alpaugh K, Hedlund G, Forsberg G, Langer C, Rogatko A, Hawkins R, Dueland S, Lassen U, Cohen RB. Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2009;27:4116-23.
  • Borghaei H, Alpaugh RK, Bernardo P, Palazzo IE, Dutcher JP, Venkatraj U, Wood WC, Goldstein L, Weiner LM. Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): A Trial Coordinated by the Eastern Cooperative Oncology Group. J Immunother. 2007;30:455-467.
  • Borghaei H, Binyamin L, Astsaturov I, Weiner AM. Antibody therapy of cancer. In: Molecular Targeting in Oncology. (Kaufman, H.L., Wadler, S., Antman, K., eds.), pp. 371-412. Humana Press, Totowa, NJ, 2008. Book Chapter
  • Borghaei H, Langer CJ, Millenson M, Ruth KJ, Litwin S, Tuttle H, Seldomridge JS, Rovito M, Mintzer D, Cohen R, Treat J. Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017. J Thorac Oncol. 2008;3:1286-1292.
  • Borghaei H, Mehra, R., Simon, G. Current issues in adjuvant chemotherapy for resected, stage IB non-small-cell lung cancer. Fut Oncol. 2009;5:19-22.
  • Borghaei H, Robinson MK, Weiner LM. Monoclonal antibody therapy of cancer. In: Immunotherapy of Cancer (Disis, M.L., ed.), pp. 487-502. Humana Press, Totowa, NJ, 2006.
  • Borghaei H Smith MR, Campbell KS. Immunotherapy of cancer. Eu J Pharmacol. 2009;625:41-54.
  • Carcereny E, Moran T, Felip E, Borghaei H, Fitzgerald T, Clark J, Guan S, Hsu K, Beckman R, Yan L, Rosell R, Johnson DH. An open label, randomized Phase I/IIA Trial evaluating MK-0646, an anti-IGF-1R monoclonal antibody (MoAB), in combination with erlotinib for patients with recurrent non-small cell lung cancer (NSCLC). 13th World Conference on Lung Cancer, San Francisco, July, 2009. Conference
  • Faller BA, Robu VG, Borghaei H. Therapy-related acute myelogenous leukemia with an 11q23/MLL translocation following adjuvant cisplatin and vinorelbine for non-small-cell lung cancer. Clin Lung Cancer. 2009;10:438-440.
  • Huang C, Treat J, Borghaei H, Millenson MM, Mintzer DM, Cohen RB, Staddon AP, Seldomridge J, Langer CJ. Promising survival in patients with recurrent non small cell lung cancer (NSCLC) treated with docetaxel and gemcitabine in combination as second line therapy. J Thorac Oncol. 2008;3:1032-1038. Not supported by NIH funding
  • Kurzrock R, Fayad L, Voorhees P, Furman RR, Lonial S, Borghaei H, Jagannath S, Sokol L, Cornfeld M, Qi M, Jiao T, Herring J, Qin X, van Rhee F. A Phase I study of CNTO 328, an anti-interelukin-6 monoclonal antibody in patients with A-cell non-hodgkin's lymphoma, multiple myeloma, or Castleman's disease, pp. 371-372, 2008. Book Chapter
  • Narra K, Borghaei H, Al-Saleem T, Hoeglund M, Smith MR. Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: Report of two cases and review of the literature. Leuk. Res. 2005;30:109-114.
  • Robinson MK, Borghaei H, Adams GP, Weiner LM. Pharmacology of cancer biotherapeutics – monoclonal antibodies. In: Cancer: Principles and Practice of Oncology (DeVita, V.T., Hellman, S., Rosenberg, S.A., eds.), pp. 537-547. Lippincott Williams & Wilkins, 2008. Book Chapter
  • Shafer D, Borghaei H, Millenson M, Nicolaou N, Al-Saleem TI, Leasure NC, Padavic K, Smith MR, Schilder RJ. Vinblastine, mitoxantrone and prednisone (MVP) followed by involved field radiotherapy (IF-XRT) for early clinical stage Hodgkins's lymphoma: Long term follow-up. Blood. 2005;106:751A-751A.
  • Shafer, D., Smith, M.R., Litwin, S., Li, T., Borghaei H, Al-Saleem, T.I. Peripheral blood CD3(+)CD4(+) and CD3(-)CD56(+) cell counts and circulating lymphoma cells are significant predictors of overall survival in newly diagnosed follicular lymphoma. Blood. 2007;110:767A-768A.
  • Shafer D, Wu H, Al-Saleem T, Reddy K, Borghaei H, Lessin S, Smith M. Cutaneous precursor B-cell lymphoblastic lymphoma in 2 adult patients: clinicopathologic and molecular cytogenetic studies with a review of the literature. Arch Dermatol. 2008 Sep;144(9):1155-62. Accepted prior to April 7, 2008
  • Smith M, Borghaei H. Comment on Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: A Wisconsin Oncology Network Study, by Kahl et al., Cancer Invest. 2005;23:13-18.
  • Smith MR, Borghaei H. Comment on phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: A Wisconsin Oncology Network Study," by Kahl et al. Cancer Invest. 200523:572.
  • Weiner LM, Borghaei H. Targeted therapies in solid tumors: Monoclonal antibodies and small molecules. Hum Antibodies. 2006;15:103-111.